New hope for tough ovarian cancer: drug combo trial launches
NCT ID NCT07591831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every two weeks, with scans every eight weeks to check progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- New drug cocktail aims to shrink recurrent ovarian tumors
- Could centralized surgery boost ovarian cancer survival?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New PET tracer aims to spot hidden cancer spread in the abdomen